PFE
Pfizer Inc.
PFE's fundamentals are mixed, but it looks expensive: trading at 41x earnings, more than twice its usual 15x. Its downside scenario is about four times its upside.
PFE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Weak |
PFE's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is weak.
PFE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $6.78 | -76% |
| Forward | 10x | $28.83 | — |
| Fair | 15x | $10.59 | -63% |
| Expensive | 24x | $16.53 | -43% |
| Current | 41x | $28.83 | — |
Historical ranges are pointers, not guarantees.
PFE's PE is in its expensive range at 41x. On analysts' estimates for next year's earnings, today's price would be 10x, in its cheap range.
PFE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect PFE's profitability to improve, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
PFE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.83 | +304% |
| Q3 2026 | $0.70 | -59% |
| Q2 2026 | $0.76 | -60% |
| Q1 2026 | $1.31 | -5.1% |
| Q4 2025 | $1.36 | -3.5% |
| Q3 2025 | $1.72 | +129% |
| Q2 2025 | $1.88 | +$2.33 |
| Q1 2025 | $1.38 | +$1.43 |
| Q4 2024 | $1.41 | +281% |
PFE's earnings per share have fallen from their peak: $0.70 over the past year, against $5.47 in late 2022.
PFE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.6B | -0.4% |
| Q2 2026 | $15B | +2.6% |
| Q1 2026 | $14.5B | +5.4% |
| Q4 2025 | $17.6B | -1.2% |
| Q3 2025 | $16.7B | -5.9% |
| Q2 2025 | $14.7B | +10% |
| Q1 2025 | $13.7B | -7.8% |
| Q4 2024 | $17.8B | +25% |
PFE's revenue fell from its 2022 peak and has held roughly level since: $16.6B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +0.4 points |
| Q2 2026 | -4.3% | -25 points |
| Q1 2026 | 22% | +1.6 points |
| Q4 2025 | -9.3% | -9.3 points |
| Q3 2025 | 20% | -6.6 points |
| Q2 2025 | 21% | +22 points |
| Q1 2025 | 20% | -2.7 points |
| Q4 2024 | -0.1% | +29 points |
PFE's operating margin was 20% last quarter, about level with the same quarter a year ago.
PFE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | +20% |
| Q2 2026 | $302M | +$1.5B |
| Q1 2026 | $2.2B | +23% |
| Q4 2025 | $4.5B | -22% |
| Q3 2025 | $4B | -34% |
| Q2 2025 | -$1.2B | +$1.2B |
| Q1 2025 | $1.8B | +359% |
| Q4 2024 | $5.8B | +38% |
PFE still generates free cash flow, though less than at its 2021 peak: $11.8B over the past year.
PFE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +52M shares |
| 1 year | +0.6% | +37M shares |
| 3 years | +1.9% | +105M shares |
| 5 years | +0.5% | +26M shares |
| Available history | -3.9% | -230M shares |
PFE has 5.8B diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | $2B |
PFE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.7x | High |
| Q2 2026 | 5.8x | High |
| Q1 2026 | 4.3x | High |
| Q4 2025 | 4.5x | High |
| Q3 2025 | 3.8x | Elevated |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 4.3x | High |
| Q4 2024 | 4.2x | High |
PFE's net debt is about 5.7 years of its operating earnings (EBITDA), up from 3.8 years a year ago.
PFE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.8 | Neutral |
| Stochastic | 72.5 | Neutral |
PFE's weekly RSI is 57 (neutral) and its Stochastic is 73 (neutral).
PFE PE vs Healthcare Sector
| Metric | PFE | Sector median | Relative |
|---|---|---|---|
| PE | 41x | 26x | 59% above |
| PE % | 97 | 29 | 68 pts above |
PFE is trading at 41x earnings, a 59% premium to the Healthcare sector's median of 26x.
PFE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 1.1% below |
| 20 week MA | $27.5 | 4.9% above |
| 50 week MA | $26.8 | 7.7% above |
| 100 week MA | $25.8 | 12% above |
| 200 week MA | $29.0 | 0.4% below |
PFE's trend is mixed: it's above three of its five weekly moving averages, and 0.4% below its 200-week average.
PFE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.3 | $37.3 | 0% |
| 2021 | $37.3 | $58.7 | +58% |
| 2022 | $58.7 | $51.8 | -12% |
| 2023 | $51.8 | $28.8 | -44% |
| 2024 | $28.8 | $26.6 | -7.5% |
| 2025 | $26.6 | $25.1 | -5.7% |
| 2026 YTD | $25.1 | $28.8 | +15% |
PFE has finished four years in a row lower, and it's up 15% so far in 2026.